Rob Finch

Prolaris is teaming up with PathomIQ for a genomic-pathAI joint initiative which is pretty exciting; in the meantime, useful meta-analysis of results to date over the years @myriadgenetics #GU26

We’re excited to share data from seven studies at the upcoming 2024 @ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the our Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™. Read the press release: brnw.ch/21wK5dI

I grew up in the arts and have always felt like science and art complement one another. I’m particularly passionate when medicine and art collide. I love that we’ll get to see the pre-Broadway run of @DeathBecomesBwy while attending #ASCO2024 @myriadgenetics @ProlarisTest

Heading to Chicago for this year’s @ASCO Annual Meeting. Happy to meet with anyone who has questions about the genetics and genomics of #ProstateCancer and how to incorporate testing into your practice. @ProlarisTest @MyriadMyRisk #PreciseTumor @myriadgenetics #ASCO2024

Recently published data indicate that the Prolaris Test can accurately predict which patients may benefit from adding ADT to radiation therapy for prostate cancer. #pcsm #urology @prostatemd @huntsmancancer @Huntsman_GU urologytimes.com/view/cell-cycl…

Today we announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer. Read the press release: brnw.ch/21wJR6d

At @ASCO #GU24? Come by the poster session, Board P5 to see our poster “Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate risk prostate cancer” @ProlarisTest @myriadgenetics

When the waiter wants to join in on the @myriadgenetics fun!! @ShellyCumming18 @natascha_saylor @RobFinchCGC #NSGC23

Today at #NSGC23: Join us for a CEU Lunch Symposium - Patients, Partnership, and Purpose: A Panel Discussion​, 12:45-2pm. #Cancer and #prenatal patients share their experience with #genetictesting and screening alongside genetic counselors and scientists, discussing the clinical details and the technology that made it possible. #GeneChat Learn more: myriad.com/NSGC

Drop by the Myriad booth at the NSGC Annual Education Conference to update your headshot! You’re bound to get some good networking opportunities in this line! Booth #317 @myriadgenetics @MyriadMyRisk #NSGC23

If you are attending #NSGC23, visit the Myriad Genetics booth #317 and learn how genetic insights can help to improve the health and well-being of patients. Learn more: brnw.ch/21wDuPg #GeneChat

Will you be in Chicago for #NSGC23? Join us on October 20 from 7 p.m. to 10 p.m. at the John Hancock Building for our 10th Annual Genetic Counselor Appreciation Night and Fundraiser! We're looking forward to a fun night of: 📣 Good conversation 🎵 Music 🍕 Food 💫 Taking a spin on the 360 Chicago TILT Tide (ideally not too soon after enjoying the food....) Learn more: myriad.com/nsgc/ #GeneChat #Chicago

Attending #ASTRO2023? Come by our booth to learn how Prolaris can help with ADT decision-making. Myriad Genetics. Booth 3614 @ProlarisTest @myriadgenetics

Check out our poster “Active Surveillance Selection and Durability in Men with NCCN Intermediate Risk, Localized Prostate Cancer Who Had Genetic Testing” being presented at #WSAUA23. @ProlarisTest @myriadgenetics

Explore the cutting-edge enhancement to the Prolaris test and its impact on precision medicine. Don't miss this opportunity to learn from leading experts in the field and stay at the forefront of advancements in #prostatecancer care. Register today! fal.cn/3Afv9

Thanks to everyone who stopped by Dr. Tward’s poster presentation on “Predicting Absolute Benefit in Risk of Metastasis of #ADT added to Radiation Therapy in Patients with Newly Diagnosed #ProstateCancer” @RobFinchCGC #ASCO23

Join us at this morning’s poster session at #ASCO23. Come by Board 124 to discuss with Dr Tward “Predicting Absolute Benefit in Risk of Metastasis of ADT added to Radiation Therapy in Patients with Newly Diagnosed Prostate Cancer” @ProlarisTest @myriadgenetics

To help raise awareness and educate men on the various aspects of the #ProstateCancer journey, we’ve created a free eBook to provide valuable information from time of diagnosis to treatment options to patient resources and much more. View eBook fal.cn/3yHCK